CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value
CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in…
A Novel Agent SL-401 Triggers Anti-Myeloma Activity by Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism
A Novel Agent SL-401 Triggers Anti-Myeloma Activity by Targeting Plasmacytoid…
SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1)/Chromosome Region Maintenance-1 (CRM1) With Broad and Potent Anti-Cancer Activity.
SL-801, a novel, reversible inhibitor of Exportin-1 (XPO1) / Chromosome Region…
SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels
SL-401 Activity Against AML Blasts and Its Correlation With CD123 Levels. AACR…
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis
SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor…
Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on Myeloproliferative Neoplasms
Expression of CD123 (IL-3R-alpha), a Therapeutic Target of SL-401, on…
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia
SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R),…
SL-501, a Next-Generation Targeted Therapy Directed at the IL-3 Receptor, Possesses Preclinical Anti-Tumor Activity Against Hodgkin’s and Non-Hodgkin’s Lymphoma
SL-501, a Next-Generation Targeted Therapy Directed at the IL-3 Receptor,…
SL-501, a Next-Generation Targeted Therapy Directed to IL-3R, Inhibits the Growth of Tyrosine Kinase Inhibitor-Resistant CML Cells
SL-501, a next-generation targeted therapy directed to IL-3R, inhibits the…
Effect of a Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) on Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Osteolytic Bone Disease
Effect Of A Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) On…